### Bringing in the Research Dollars! (BiRD)



#### Presented by: The Emory+Children's Pediatric Research Center

The monthly BiRD announcement highlights pediatric research funding opportunities

Contact <u>stacy.heilman@emory.edu</u> with questions on the funding opportunities highlighted below or for general research grant application advice

#### November 2011 BIRD highlights

- ❖ Additional details and information on the NIH <u>Transformative Research Awards</u> program
- Other NIH opportunities related to <u>improving treatment adherence in HIV-Positive</u> <u>Adolescents and Young Adults</u> and availability of funds for pilot and feasibility <u>clinical research studies in kidney or urological disease</u>
- ❖ Several American Heart Association opportunities that all fund research that can be just broadly related to cardiovascular function and disease and stroke including a junior to mid career level Grant-in-Aid award and career development opportunities for clinical researchers, fellow-to-faculty awards and for general scientist development
- ❖ Other career development award opportunities for <u>cancer researchers</u> and announcing the ACTSI KL2 program description
- ❖ Funds available to <u>explore new ideas in cardiovascular nanomedicine</u> and for <u>travel</u> grants for PhD researchers
- ❖ Notices related to <u>NIDDK</u> and <u>NHLBI's</u> intent to no longer accept unsolicited applications through the parent R21 mechanism (specific R21 RFA's and PA's may still be offered by these institutes though)

#### GENERAL FEDERAL/COLLABORATIVE POTENTIAL

**Program/Link NIH Director's Transformative Research Awards (R01)** 

http://grants.nih.gov/grants/guide/rfa-files/RFA-RM-11-006.html

**Purpose** 

The NIH Director's Transformative Research Awards complements NIH's traditional, investigator-initiated grant programs by supporting individual scientists or groups of scientists proposing groundbreaking, exceptionally innovative, original and/or unconventional research with the potential to create new scientific paradigms. Little or no preliminary data are expected.

Projects must clearly demonstrate potential to produce a major impact in a broad area of biomedical or behavioral research.

Projects in any area of NIH interest, including basic, clinical, translational and behavioral studies, are encouraged and will be considered responsive to this FOA. Though technical and conceptual risks are expected in highly innovative projects, clinical research also must contend with potential risk to human subjects. Clinical researchers should not be dissuaded from submitting applications as long as rigorous assessment of participant risk/benefit ratios compellingly indicates the ratio to be in favor of the potential benefit.

**Funds Avail** 

Application budgets are not limited, but need to reflect actual needs of the proposed project. The maximum period is 5 years.

**Deadline** 

January 12, 2012

(LOI due December 12, 2011)

Remarks

Although this RFA was already highlighted in the October BiRD, we are including it here again to convey some additional information recently released by the NIH. Please see below for some highlights and feel free to contact <a href="mailto:stacy.heilman@emory.edu">stacy.heilman@emory.edu</a> if you have questions regarding interpretation of this RFA.

- > Team science is highly encouraged
- ➤ Little or no preliminary data are expected
- ➤ Research ideas that could be supported through a conventional R01 will not be suitable for this RFA
- Clinical & Behavioral research is within the scope of this RFA (17 out of 80 TR01 projects last year included human subjects)
- ➤ Questions about the scope and intent of the Transformative Research Awards initiative should be directed to Ravi Basavappa, Ph.D. in the NIH Office of the Director at Transformative Awards@mail.nih.gov
- ➤ A list of frequently asked questions can be found at this url: http://commonfund.nih.gov/TRA/faq2012.aspx

# Program/Link Improving Adherence to Treatment Regimens for HIV-Positive Adolescents and Young Adults (R01)

http://grants.nih.gov/grants/guide/rfa-files/RFA-HD-12-206.html

**Purpose** 

The purpose of this funding opportunity announcement (FOA) is to stimulate research projects that will develop, implement, and evaluate new or adapted interventions to improve adherence to medical and/or behavioral regimens for HIV-positive adolescents (11-21 years) and young adults (21-24 years). Applicants may investigate individual, family, social, political, and/or contextual factors that influence adherence, and may develop new or refine existing measures of adherence, in the process of developing efficacious or

effective adherence interventions.

**Funds Avail** Application budgets are limited to a total cost amount of \$499,999 in FY 2012

and must reflect the actual needs of the proposed project. The total project period for an application submitted in response to this funding opportunity

may not exceed 5 years.

**Deadline** February 21, 2012

Remarks A multidisciplinary group from Dept of Pediatrics and Rollins School of

Public Health is working on an application in response to this FOA.

Please contact stacy.heilman@emory.edu if you would like to learn more.

## Program/Link Pilot and Feasibility Clinical Research Grants in Kidney or Urologic Diseases (R21)

http://grants.nih.gov/grants/guide/pa-files/PAR-11-352.html

**Purpose** 

This Funding Opportunity Announcement (FOA) issued by the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, is to support Exploratory/Developmental Research Grants (R21) that propose small scale or pilot and feasibility clinical and translational research studies, including epidemiological studies or clinical trials related to kidney or urologic disease research. Studies should address important clinical and translational questions and are potentially of high clinical and public health impact. It is anticipated that some projects supported by these grants may lead to full-scale clinical studies including diagnostic strategies, epidemiological studies, or randomized clinical trials of diagnosis, prevention, or treatment of kidney or urologic diseases.

**Funds Avail** 

The combined budget for direct costs for the two-year project period may not exceed \$275,000. No more than \$200,000 may be requested in any single year. Applicants may request direct costs in \$25,000 modules, up to the total direct costs limitation of \$275,000 for the combined two-year award period.

**Deadline** 

Standard NIH Due Dates\*

Remarks

- Applications for R21 awards should describe projects distinct from those supported through the traditional R01 mechanism.
- ➤ The R21 mechanism is intended to encourage new exploratory and developmental research projects. These studies may involve considerable risk but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, or applications that could have a major impact on a field of clinical research.
- Studies proposed via the R21 mechanism should have the potential to break new ground or extend previous discoveries toward new directions or applications
- ➤ Basic laboratory research, studies of laboratory animals, studies that do not involve human subjects or are not human studies should be

submitted via the Parent R21 (PA-11-261:

http://grants.nih.gov/grants/guide/pa-files/PA-11-261.html, although according to NOT-DK-12-001, NIDDK will no longer participate in the Parent NIH Exploratory Developmental Research Grant (R21) Funding Opportunity Announcement after the Nov 16, 2011, deadline. See more details on NOT-DK-12-001, highlight below.

#### **FOUNDATION**

#### Program/Link The Gerber Foundation

http://www.gerberfoundation.org/

The primary focus of grantmaking is on health and nutritional issues **Purpose** 

> affecting infants and young children from the first year before birth to 3 years of age. Research projects aimed at finding solutions to children's health and nutritional problems are sought. Of particular interest are those offering a substantial promise of meaningful advances in prevention and treatment of diseases and those with broad applicability to the general population.

**Funds Avail** Awards and time periods vary depending upon the specific project. Research

projects may be no longer than 3 years in length. Total grant size should be

no more than roughly \$300,000.

**Deadline** Concept paper due Dec 1 (upon invitation, full proposal is due Feb 15th)

Remarks Foundation grants are not typically ongoing. Supported projects should have beginnings and endings, reasonable periods during which

measurable progress or outcomes are accomplished.

Determination of interest in receiving a full proposal will be made by Dec  $20^{th}$ 

#### Program/Link American Heart Association Grant-in-Aid, Greater Southeast Affiliate

http://my.americanheart.org/professional/Research/FundingOpportunities/Su pportingInformation/Winter-2012---Greater-Southeast-Affiliate-Grant-in-Aid\_UCM\_431355\_Article.jsp#.TrxPglYfgxg

**Purpose** Funds research broadly related to cardiovascular function and disease and

stroke, or to related clinical, basic science, bioengineering or biotechnology, and public health problems, including multidisciplinary efforts. Proposals are encouraged from all basic disciplines as well as epidemiological, behavioral, community and clinical investigations that bear on cardiovascular

and stroke problems.

\$82,500 (\$75,000/yr. plus \$7,500 indirect costs) for 2 years max. Up to **Funds Avail** 

\$25,000 per year may be used for salary/fringe of the principal investigator,

collaborating investigators and others with faculty appointments.

**Deadline** Jan 23, 2012

**Remarks** ➤ This opportunity appears to be most suited for junior/mid level

investigators since at the time of award activation, the amount of other

- research funding available to the principal investigator may not exceed \$250,000 annually, including direct funds only, but does not include PI salary/fringe and intramural funding.
- At the time of application, the applicant must hold a faculty/staff appointment (or equivalent), and must be conducting independent research. Not intended for people in research training or fellowship positions.

### CAREER DEVELOPMENT/TRAINING

# Program/Link American Heart Association Clinical Research Program, Greater Southeast Affiliate

http://my.americanheart.org/professional/Research/FundingOpportunities/For Scientists/Winter-2012---Greater-Southeast-Affiliate-CRP-Description\_UCM\_431674\_Article.jsp#.TrxQcFYfgxg

#### **Purpose**

To encourage early career investigators who have appropriate and supportive mentoring relationships to engage in high quality introductory and pilot clinical studies that will guide future strategies for reducing cardiovascular disease and stroke while fostering new research in clinical and translational science, and encouraging community- and population-based activities. Funding is available for research related to cardiovascular disease and stroke prevention or treatment, or to related clinical and public health problems, including multidisciplinary efforts. Proposals are encouraged on provider behavior, patient behavior, behavioral outcomes, risk factor outcomes, disease outcomes, cost benefit analyses, efforts to evaluate outcomes of patient care delivery and patient/provider and/or system compliance and adherence to recommendations, as well as pilot clinical research studies that may provide preliminary data for larger-scale investigation. Studies using existing databases, ancillary studies or a clearly defined sub-study of an ongoing clinical research study are also encouraged. There must, however, be clear justification that the proposal is a sub-study and not a piece of an already funded project.

#### **Funds Avail**

\$71,500K annually for a total of 2 years

#### **Deadline**

Jan 23, 2012

#### **Remarks**

- ➤ This grant does not fund basic science or support senior researchers, but encourages mentoring of early career investigators.
- ➤ The amount of other research funding available to the principal investigator, at the time of award activation, may not exceed \$150,000 per year (direct funds exclusive of PI salary/fringe and intramural funding).
- ➤ The Clinical Research Program grant <u>can</u> be held concurrently with an NIH K award, within certain limitations.

Program/Link American Heart Association Scientist Development Grant, National

http://my.americanheart.org/professional/Research/FundingOpportunities/Su pportingInformation/Winter-2012---National-Scientist-Development-Grant\_UCM\_321916\_Article.jsp#.TrxQ01Yfgxg

#### **Purpose**

To support highly promising beginning scientists in their progress toward independence by encouraging and adequately funding research projects that can bridge the gap between completion of research training and readiness for successful competition as an independent investigator. Research broadly related to cardiovascular function and disease and stroke, or to related clinical, basic science, bioengineering or biotechnology, and public health problems, including multidisciplinary efforts.

#### **Funds Avail**

\$77K annually for 4 years

#### **Deadline**

January 26, 2012

#### Remarks

- AHA supports research broadly related to cardiovascular function and disease and stroke, or to related clinical, basic science, bioengineering or biotechnology, and public health problems, including multidisciplinary efforts.
- At the time of award activation, the applicant must hold a faculty/staff position up to and including the rank of assistant professor (or equivalent). Applications may be submitted for review in the final year of a postdoctoral research fellowship or in the initial years of the first faculty/staff appointment.
- At the time of award activation, no more than four years will have elapsed since an applicant's first faculty/staff appointment

The Scientist Development Grant may not be held concurrently with an NIH K award

#### Program/Link American Heart Association Fellow-to-Faculty Transition Award, **National**

http://my.americanheart.org/professional/Research/FundingOpportunities/For Scientists/Winter-2012---National-FTF-Transition-Award\_UCM\_431606\_Article.jsp#.Tr13MIYfgxg

#### **Purpose**

This program provides funding for trainees with outstanding potential for careers as physician-scientists in cardiovascular or stroke research during the crucial period of career development that spans the completion of research training through the early years of the first faculty/staff position. The award provides a supportive mentored experience during this period of transition. The award will (1) greatly enhance the awardee's chances of obtaining a high-quality faculty/staff appointment; (2) improve the awardee's success and retention in an investigative career in cardiovascular science; and (3) develop the mentoring skills of the awardee as a potential future mentor.

#### **Funds Avail**

Training stage of award - \$65,000 annually (for 1-3 years) Faculty stage of award - \$132,000 annually

Maximum of 5 years of support total

#### **Deadline**

Jan 26, 2012

#### Remarks

- ➤ AHA supports research <u>broadly related</u> to cardiovascular function and disease and stroke, or to related clinical, basic science, bioengineering or biotechnology, and public health problems, including multidisciplinary efforts is supported.
- ➤ Since the fellowship is considered a training award, a faculty appointment cannot be held upon award (exceptions are M.D. or M.D./Ph.D. with clinical responsibilities who hold a title of instructor or similar due to their patient care responsibilities but who devote at least 80 percent full-time effort to research training)
- ➤ Individual awardees may take the award from the institution providing the research training component to another institution for the career development component (first faculty/staff appointment). The intent is to make the awardee a "free agent" who is empowered to stay at or move from the training institution while retaining the award. The mentor during the faculty stage of the award may or may not be the same person who was the mentor during the training phase.
- At least 80% research/training effort is expected during the training period and 75 % effort towards research is required during the faculty component of the award.
- > Prior or current recipients of any NIH K-series awards are not eligible.

### Program/Link Sidney Kimmel Foundation for Cancer Research

http://www.kimmel.org/Application\_Process37.html

#### **Purpose**

#### The Kimmel Scholar Award

The Kimmel Foundation is seeking accomplished young investigators dedicated to a career in cancer research. *These awards are designed for researchers who do not yet have their own R01 funding*. Applicants will be judged on the basis of quality of prior work, research proposed and letters of support. Funding of awards will be subject to execution of binding agreements setting forth terms and conditions under which scholarships will be provided. Applicants for 2012 awards will be notified by mid-April, 2012.

#### The Kimmel Translational Science Award

The Foundation provides up to five additional awards specifically for physicians engaged in translational science. Candidates must <u>not</u> hold R01 funding for the laboratory component of their cancer research. Applicants must demonstrate a significant personal involvement in the laboratory component of the translational project described. The translational research may involve primarily animal studies but must include reasonable application

to subsequent human investigation.

**Funds Avail** 

\$100,000 per year for 2 years

**Deadline** 

December 1, 2011 at noon EST

Remarks

- For the Kimmel Scholar Award, applications are limited to those who achieved the equivalent rank of Assistant Professor on or after July, 2008. However, physicians who have both clinical and research responsibility are eligible if appointed on or after July, 2007.
- For the Kimmel Translational Science Award, eligibility includes those with M.D. or equivalent degrees, who have achieved the rank of Assistant Professor on or after July, 2007.
- ➤ See FAQ's for more information: http://www.kimmel.org/FAQs40.html

#### Program/Link Mentored Clinical & Translational Research Scholars ACTSI KL2 **Program**

http://www.actsi.org/areas/retcd/kl2/index.html

**Purpose** 

Junior faculty members at the MD or PhD level from a wide variety of disciplines at Emory University, Morehouse School of Medicine, or Georgia Institute of Technology who are committed to an academic career in clinical and/or translational research and who have excellent potential to become an independent clinical investigator are encouraged to apply to the KL2 – Mentored Clinical and Translational Research Scholars (MCTRS) Program. The KL2 award provides support for didactic and mentored research training for junior faculty members committed to a career in clinical investigation.

**Funds Avail** 

For 75% salary support, a \$25,000/ year KL2 technical budget for research costs and tuition, and some salary support for the KL2 scholar's Lead Mentor.

**Deadline** 

March 1, 2012

Remarks

- ➤ KL2 award recipients must devote 75% professional effort to the program (surgeons may devote 50% effort).
- > Partial or matching salary support from the applicant's Division, Department or other non-federal sources is highly encouraged but not required.
- > Mentor required

Previous Emory Dept of Pediatrics KL2 awardees Drs. Andi Shane (ashane@emory.edu) and Anne Fitzpatrick (anne.fitzpatrick@emory.edu) have invited those interested in this program to contact them to ask about the application and program requirements

Please contact <u>stacy.heilman@emory.edu</u> for pediatrics specific support and guidance, if you intend to apply for this KL2 opportunity

#### INTRAMURAL/SEED/PILOT

#### Program/Link Center for Translational Cardiovascular Nanomedicine (CTCN) Seed Grant Program

#### **Purpose**

Cardiovascular disease remains the leading cause of death in the US, and there is an un-met need to inform the state and activity of atherosclerotic plaques, to deliver therapeutics directly to lesions, and to guide the evaluation of therapy. Nanotechnology has the potential to address these challenges. The vision of the Center for Translational Cardiovascular Nanomedicine (CTCN) is to develop and apply nanotechnology and biomolecular engineering tools and approaches to address the compelling medical needs in the detection and treatment of atherosclerosis and the repair of damaged vasculature and heart tissue. Currently the CTCN has four major research theme areas:

- 1) nanoparticle based PET and dual-modality PET/MR contrast agents for in vivo imaging of atherosclerotic plaques
- 2) fluorescence imaging probes and gold-nanoparticle sensors for in vitro detection of atherosclerosis
- 3) nanocarriers for targeted delivery of siRNA and drug molecules to lesions in vivo
- 4) nanotools in stem cell research for personalized repair of damaged tissue.

The goals of the CTCN are to establish the nano-toolbox and nanocardiology knowledge-base, to translate the nano-scale tools and technologies to clinical applications in the detection and treatment of cardiovascular disease, and to train the next generation of leaders in cardiovascular nanomedicine. This seed grant program will help achieve the goals of the CTCN, explore new ideas in cardiovascular nanomedicine, and facilitate the development of new collaborations between Georgia Tech and Emory University in cardiology and molecular imaging.

#### **Funds Avail**

\$50K for one year

#### **Deadline**

December 1, 2011

#### **Remarks**

- All faculty members at Georgia Institute of Technology and Emory University are welcome to submit proposal(s) to this seed grant program. However, the following requirements must be met:
  - 1. The proposed research should be consistent with the vision and goals of the CTCN
  - 2. Two investigators, one from Georgia Tech and the other from Emory, should serve as co-PIs of the proposed project

- 3. The proposed research project should have a high probability of receiving NIH funding for subsequent studies.
- Contact <u>amy.tang@bme.gatech.edu</u> with questions and for further information about application requirements

#### Travel

## Program/Link Burroughs Wellcome Fund Collaborative Research Travel Grants

http://www.bwfund.org/pages/481/Collaborative-Research-Travel-Grants/

#### **Purpose**

This program provides support for researchers from degree-granting institutions to travel either domestically or internationally to a laboratory to acquire a new research technique, to facilitate a collaboration, or to attend a laboratory/lecture course. Applicants must hold a Ph.D. or currently studying in a Ph.D. program in mathematics, physics, chemistry, computer science, statistics, or engineering interested in investigating research opportunities in the biological sciences. *Biologists interested in working with physical scientists, mathematicians, engineers, chemists, statisticians, or computer scientists to incorporate their ideas and approaches to answering biological questions are eligible.* 

**Funds Avail** 

Up to \$15,000

**Deadline** 

December 1, 2011 by 4:00 p.m., Eastern Time

Remarks

- Applicants must be citizens or permanent residents of the U.S. or Canada at the time of application.
- ➤ Biologists interested in working with physical scientists to answer biological questions are eligible to apply.

#### **NOTICES/ANNOUNCEMENTS**

NIDDK Will No Longer Participate in the Parent NIH Exploratory Developmental Research Grant (R21) Funding Opportunity Announcement

http://grants.nih.gov/grants/guide/notice-files/NOT-DK-12-001.html

The NIDDK will no longer co-sponsor the NIH Exploratory Developmental Research Grant Program (Parent R21) and will not accept any applications (new or resubmission) in response to the Parent R21 Funding Opportunity Announcement (FOA) after the expiration of PA-10-069 (i.e., for receipt dates after Cycle III for funding consideration during the May 2012 Council round). NIDDK will not accept any R21 applications submitted to the Parent R21 FOA for consideration in Council rounds after the May 2012 round whether those applications are submitted under the expiring Parent R21 FOA PA-10-069 or to the new Parent R21 FOA PA-11-261.

NIDDK will continue to accept R21 applications for pilot projects for clinical studies/trials and secondary data analyses under separate <a href="Program Announcements">Program Announcements</a>.

NHLBI Will No Longer Participate in the Parent NIH Exploratory Developmental Research Grant (R21) Funding Opportunity Announcement

http://grants.nih.gov/grants/guide/notice-files/NOT-HL-11-154.html

The NHLBI is discontinuing funding of new R21 applications in response to the NIH's Parent Funding Opportunity Announcement (FOA), NIH Exploratory Developmental Research Grant Program (Parent R21). Hence, the NHLBI will no longer be a co-sponsor for the NIH R21 Parent Announcement. The FOA at the time of release of this Notice is PA-10-069. The NHLBI will not accept new (A0) R21 applications in response to the Parent R21 FOA for the Cycle III due dates (October 16, 2011 or January 7, 2012 for AIDS applications) or any date thereafter. The NHLBI will accept resubmission (A1) R21 applications through Cycle I, 2012 (March 16, 2012 or May 7, 2012 for AIDS applications). Starting with Cycle II, 2012 and thereafter, NHLBI will not accept any R21 applications in response to the NIH Exploratory Development Research Grant Program (Parent R21) (PA-11-261).

This Notice does not change NHLBI's participation in any other FOAs, including those that use the R21 activity code.

In the future, the NHLBI may issue highly targeted Funding Opportunity Announcements for R21 grant applications when scientific opportunities and needs arise that will benefit from the features and requirements of the R21 activity code.

#### NIH STANDARD DUE DATES CITED ABOVE

	Cycle I	Cycle II	Cycle III
Mechanism(s)	Due Date	Due Date	Due Date
P Series			
ALL – new, renewal,	25-Jan	25-May	25-Sept
resubmission, revision			
R01			
NEW	5-Feb	5-Jun	5-Oct
renewal, resubmission, revision	5-Mar	5-Jul	5-Nov
R41, R42, R43, R44, U43, U44,			
All - new, renewal, resubmission,			
revision	5-April	5-Aug	5-Dec
R03, R21, R34			
NEW	16-Feb	16-Jun	16-Oct
renewal, resubmission, revision	16-Mar	16-Jul	16-Nov
K series			
NEW	12-Feb	12-Jun	12-Oct
renewal, resubmission, revision	12-Mar	12-Jul	12-Nov
All AIDS and AIDS-Related			
Applications (for mechanisms			

cited above)  All - new, renewal, resubmission,	7-May	7-Sept	7-Jan
revision			

For the full schedule of NIH standard due dates, see <a href="http://grants1.nih.gov/grants/funding/submissionschedule.htm">http://grants1.nih.gov/grants/funding/submissionschedule.htm</a>



This compilation of general interest funding opportunities and announcements with possible collaborative potential is distributed to our pediatric research community monthly. It is compiled by the Emory-Children's Pediatric Research Center to disseminate funding announcements of potential interest in a consolidated manner. More specific announcements are distributed in a more targeted fashion.

If you are not receiving this directly from Stacy Heilman and wish to be added to our Pediatric Research listsery, please e-mail <a href="mailto:stacy.heilman@emory.edu">stacy.heilman@emory.edu</a> to make the request. Please also contact Stacy if you are interested in applying for any pediatric focused research funding opportunities and/or if you are interested in building collaborative efforts and programs towards applying for future pediatric research funding.